company background image
ECX

Epigenomics XTRA:ECX Stock Report

Last Price

€0.47

Market Cap

€7.5m

7D

11.9%

1Y

-60.0%

Updated

10 Aug, 2022

Data

Company Financials +
ECX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ECX Stock Overview

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.

Epigenomics AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Epigenomics
Historical stock prices
Current Share Price€0.47
52 Week High€1.34
52 Week Low€0.38
Beta1.17
1 Month Change2.62%
3 Month Change-5.81%
1 Year Change-59.97%
3 Year Change-96.49%
5 Year Change-98.58%
Change since IPO-98.38%

Recent News & Updates

Shareholder Returns

ECXDE BiotechsDE Market
7D11.9%-2.1%0.6%
1Y-60.0%-4.1%-20.0%

Return vs Industry: ECX underperformed the German Biotechs industry which returned -3% over the past year.

Return vs Market: ECX underperformed the German Market which returned -20.8% over the past year.

Price Volatility

Is ECX's price volatile compared to industry and market?
ECX volatility
ECX Average Weekly Movement9.1%
Biotechs Industry Average Movement8.7%
Market Average Movement5.6%
10% most volatile stocks in DE Market10.4%
10% least volatile stocks in DE Market2.8%

Stable Share Price: ECX is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ECX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199835Greg Hamiltonhttps://www.epigenomics.com

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.

Epigenomics AG Fundamentals Summary

How do Epigenomics's earnings and revenue compare to its market cap?
ECX fundamental statistics
Market Cap€7.51m
Earnings (TTM)-€3.88m
Revenue (TTM)€6.21m

1.2x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ECX income statement (TTM)
Revenue€6.21m
Cost of Revenue€139.00k
Gross Profit€6.07m
Other Expenses€9.96m
Earnings-€3.88m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 10, 2022

Earnings per share (EPS)-0.24
Gross Margin97.76%
Net Profit Margin-62.52%
Debt/Equity Ratio0%

How did ECX perform over the long term?

See historical performance and comparison